Surmodics outmaneuvers activist investor?

> Drug-delivery company Surmodics may have outmaneuvered an activist investor. Item

> Seattle-based non-profit Infectious Disease Research Institute has received a multimillion-dollar grant from the Defense Advanced Research Projects Agency to develop a novel single dose influenza vaccine to prevent a pandemic flu outbreak. The proposal combines IDRI's vaccine-adjuvant technology and a micro-needle delivery device. Story

> The Nanotechnology Knowledge Transfer Network is planning a conference to discuss the importance of nanotechnology in formulation and drug delivery. More here

> 'Liquid pistons' could drive new advances in camera lenses and drug delivery. Release

> Advances in materials technology are driving the autoinjection drug delivery device market, according to new research. Item

> Switzerland drug delivery company EffRx Pharmaceuticals has submitted an NDA to the FDA for EX101 for the prevention and treatment of osteoporosis in postmenopausal women and the incensement of bone mass in men with osteoporosis. EffRx release

> Drug delivery abstract of the week: Designing dendrimers for drug delivery and imaging: Pharmacokinetic considerations. Abstract

> Drug delivery patent application of the week: Transdermal Delivery Using Encapsulated Agent Activated by Ultrasound and or Heat. Patent application

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.